Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Bimatoprost in Men with Androgenetic Alopecia
NCT02676310Phase 1Terminated
- Sponsor
- Allergan
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bimatoprost in androgenetic alopecia (AGA) (5 cohorts), sponsored by Allergan. Primary endpoints: Percentage of Participants with Treatment Emergent Adverse Events at 42 Days, Change from Baseline in Local Dermal Tolerability at 42 Days and 1 more. Started Mar 2016; status: terminated.
02
Drugs
bimatoprost
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT02676310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02676310.